Get the Stockscreener App
0.801
3.62%
0.028
After Hours:
.81
0.009
+1.12%
Fractyl Health Inc stock is traded at $0.801, with a volume of 1.62M.
It is up +3.62% in the last 24 hours and up +7.81% over the past month.
Fractyl Health Inc is a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D). Its Revita and Rejuva candidates are designed to target root causes of metabolic diseases, allowing the company to advance metabolic disease treatment from chronic management towards prevention and reversion of the disease. The Revita DMR System (Revita), its lead product candidate, is based on its insights surrounding the potential role of the gut in obesity.
See More
Previous Close:
$0.773
Open:
$0.7926
24h Volume:
1.62M
Relative Volume:
0.82
Market Cap:
$127.08M
Revenue:
$3,000
Net Income/Loss:
$-108.00M
P/E Ratio:
-0.5336
EPS:
-1.501
Net Cash Flow:
$-87.84M
1W Performance:
+2.59%
1M Performance:
+7.81%
6M Performance:
-62.22%
1Y Performance:
-58.28%
1-Day Range:
$0.7524
$0.8199
1-Week Range:
$0.73
$0.8199
52-Week Range:
$0.3772
$2.445
Fractyl Health Inc Stock (GUTS) Company Profile
Name
Fractyl Health Inc
Sector
Industry
Phone
781-902-8800
Address
3 VAN DE GRAAFF DRIVE, BURLINGTON
Compare GUTS vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GUTS
Fractyl Health Inc
|
0.801 | 122.64M | 3,000 | -108.00M | -87.84M | -1.501 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Fractyl Health Inc Stock (GUTS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-15-25 | Initiated | H.C. Wainwright | Buy |
| Aug-28-25 | Initiated | Ladenburg Thalmann | Buy |
| Feb-28-24 | Initiated | Evercore ISI | Outperform |
| Feb-27-24 | Initiated | BofA Securities | Buy |
| Feb-27-24 | Initiated | Morgan Stanley | Overweight |
View All
Fractyl Health Inc Stock (GUTS) Latest News
Fractyl Health Inc (GUTS) Cash Flow - TradingKey
Fractyl Health Inc (GUTS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
Fractyl Health Market Sentiment - Benzinga España
GUTS|Fractyl Health Inc|Price:0.773|Chg%:+0.016 - TradingKey
Enterprise value to revenue forward of Fractyl Health, Inc. – NASDAQ:GUTS - TradingView
Fractyl Health Inc (GUTS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Fractyl Health CEO to present at key biotech investor conferences in July and August 2026 - Pluang
Fractyl Health CEO to Join Meetings and Aug. 12 Fireside Chat - Stock Titan
Fractyl Health stock up on encouraging one-year Revita study results - MSN
Fractyl Health helps maintain weight after stopping popular obesity drugs, stock soars - MSN
Fractyl Health (GUTS) AGM 2026 Summary - Quartr
Fractyl Health (GUTS) Morgan Stanley 22nd Annual Global Healthcare Conference summary - Quartr
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI) and Fractyl Health, Inc. (GUTS) - The Globe and Mail
Price to sales forward of Fractyl Health, Inc. – NASDAQ:GUTS - TradingView
Morgan Stanley Maintains Fractyl Health(GUTS.US) With Hold Rating, Maintains Target Price $2 - Moomoo
CCORF Maintains Fractyl Health(GUTS.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Craig-Hallum Maintains Fractyl Health(GUTS.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Analysts Are Bullish on Top Healthcare Stocks: Fractyl Health, Inc. (GUTS), AbbVie (ABBV) - The Globe and Mail
Fractyl Health Stock Up on Encouraging One-Year Revita Study Results - Yahoo Finance
Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation - Sahm
Fractyl Health Helps Maintain Weight After Stopping Popular Obesity Drugs, Stock Soars - Sahm
Fractyl Health reports positive randomized data from REMAIN-1 Midpoint Cohort demonstrating durable weight maintenance one year after GLP-1 discontinuation - News-Medical
H.C. Wainwright reiterates Buy on Fractyl Health stock at $8 - Investing.com UK
H.C. Wainwright reiterates Buy on Fractyl Health stock at $8 By Investing.com - Investing.com South Africa
Fractyl Health reports one-year data from weight maintenance trial - Investing.com UK
Morgan Stanley reiterates Fractyl Health stock rating on weight maintenance data - Investing.com
Fractyl Health’s Revita Procedure Shows 84% Weight Loss Maintenance One Year After GLP-1 Discontinuation in REMAIN-1 Study – Minichart - Minichart
Fractyl gains after data for Revita procedure (GUTS:NASDAQ) - Seeking Alpha
Fractyl reports 7.8 percent weight regain with Revita - grafa.com
Fractyl Health reports one-year data from weight maintenance trial By Investing.com - Investing.com South Africa
GUTS: Revita maintains up to 84% of GLP-1-induced weight loss at one year with strong safety - TradingView
Fractyl Health Says Revita Helped Patients Keep Weight Off After Stopping GLP-1s - Yahoo Finance
12 Health Care Stocks Moving In Wednesday's Intraday Session - Sahm
GUTS: Revita enabled up to 84% weight loss retention one year after GLP-1 discontinuation - TradingView
Fractyl Health (Nasdaq: GUTS) reports 1-year Revita weight maintenance data - Stock Titan
Fractyl Health Reports Positive Randomized Data from - GlobeNewswire
Price to book forward of Fractyl Health, Inc. – NASDAQ:GUTS - TradingView
Number of shareholders of Fractyl Health, Inc. – NASDAQ:GUTS - TradingView
Fractyl Health (GUTS) Slides 3.9% as Biotech Stock Tests Support Near $0.72Force Index - dars.gov.et
Fractyl Health (GUTS) Slides 3.9% as Shares Approach Critical Support at $0.72Ichimoku Cloud - dars.gov.et
Fractyl Health (GUTS) Stock Sees Fair Value Cut As Analysts Weigh Revita Opportunity - Yahoo Finance
Fractyl Health (GUTS) Q1 2026 Earnings: Wider-than-Expected Loss, No Revenue, Shares SlipEarnings Manipulation Risk - dars.gov.et
Fractyl Health (GUTS) Tests Support Near $0.76 as Downside Pressure PersistsDealer Delta - dars.gov.et
GUTSFractyl Health Inc Options - Finviz
Fractyl Health Price Target Announced at $4.00/Share by Craig-Hallum - Moomoo
GUTS Initiates Coverage by Fractyl Health -- Price Target Set at $4.00 - GuruFocus
Fractyl Health Initiated at Buy by Craig-Hallum - Moomoo
Craig-Hallum initiates Fractyl Health stock coverage with buy rating By Investing.com - Investing.com India
Craig-Hallum initiates Fractyl Health stock coverage with buy rating - Investing.com
Craig-Hallum Initiates Fractyl Health at Buy With $4 Price Target - Moomoo
Fractyl Health Inc Stock (GUTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):